CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), an immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has approved ANKTIVA (N-803, or ...
Disease-free survival rate of 58% at 12 months (primary endpoint) and 52% at 24 months Cystectomy avoidance rate of 82% at 36 months—unmatched by any product in the field to date Disease-specific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback